Romiplostim

Romiplostim is a biologic medicine classified as a thrombopoietin receptor agonist. It stimulates the thrombopoietin receptor on bone marrow cells involved in platelet production, helping increase the number of circulating platelets. Platelets are blood components that help form clots and reduce bleeding. Romiplostim is primarily used to treat selected patients with chronic immune thrombocytopenia (ITP), an autoimmune condition in which platelet destruction and impaired platelet production can lead to low platelet counts, bruising, and bleeding. It is administered as a subcutaneous injection, usually once weekly, with the dose adjusted according to platelet counts and clinical response. Treatment is generally considered when previous therapies, such as corticosteroids or immunoglobulins, have not provided an adequate response. Romiplostim is not intended to normalise platelet counts unnecessarily; the goal is to maintain a level sufficient to reduce bleeding risk. Its effects and required dose vary between individuals, and platelet counts may fall again after treatment is stopped. Regular blood tests and clinical review are therefore essential. Important safety considerations include excessive platelet increases, blood clots, changes in bone marrow reticulin, and recurrence of thrombocytopenia after discontinuation.

Romiplostim was developed as a synthetic protein-based thrombopoietin receptor agonist to stimulate platelet production. It acts through the thrombopoietin receptor, also known as c-Mpl, and differs structurally from naturally occurring thrombopoietin. The US Food and Drug Administration (FDA) first approved romiplostim in August 2008 for adults with chronic immune thrombocytopenia who had an insufficient response to other treatments, including corticosteroids, immunoglobulins, or splenectomy. The FDA expanded its indication in December 2018 to include children aged one year and older with ITP lasting at least six months who had an inadequate response to specified previous treatments. The European Medicines Agency (EMA) authorised romiplostim in 2009 for selected patients with chronic ITP. Clinical development included randomised studies evaluating platelet responses and bleeding-related outcomes in adults and children with ITP. The treatment remains subject to regulatory restrictions and monitoring because increasing platelet production does not remove the underlying autoimmune cause of ITP and may introduce risks associated with excessive platelet counts or bone marrow changes.

Romiplostim is indicated for adults with immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy, according to the applicable product label. In the United States, it is also indicated for children aged one year and older with ITP lasting at least six months who have not responded adequately to these treatments. The precise eligibility criteria differ by jurisdiction; European authorisation includes specific provisions for adults who have undergone splenectomy and for selected adults in whom splenectomy is contraindicated. Treatment aims to maintain a platelet count that reduces bleeding risk rather than achieve a normal platelet count. Romiplostim is not a general treatment for every cause of thrombocytopenia, and use for conditions such as chemotherapy-induced thrombocytopenia should not be assumed to be an approved indication. The underlying cause of a low platelet count and the patient's previous treatments should be assessed before therapy is started.

Romiplostim is administered by subcutaneous injection once weekly. For adults with ITP, the usual starting dose is 1 microgram per kilogram of body weight per week, based on the applicable prescribing information. The dose is adjusted in increments of 1 microgram per kilogram according to platelet counts, with a maximum recommended weekly dose of 10 micrograms per kilogram under the US label. Paediatric dosing is also weight-based and requires careful adjustment and monitoring. The dose should be individualised to maintain a platelet count sufficient to reduce bleeding risk, rather than to normalise the count. Complete blood counts, including platelet counts, are generally checked weekly during dose adjustment and less frequently once a stable response is established, according to the prescribing information. Treatment may continue long term if beneficial and appropriate, but response should be reassessed regularly. If the platelet count does not improve adequately despite the maximum recommended dose, the need for continued therapy should be reviewed. After discontinuation, platelet counts must be monitored because thrombocytopenia and bleeding risk can recur.

Common adverse effects of romiplostim may include headache, joint or muscle pain, dizziness, nausea, abdominal discomfort, and sleep-related symptoms. Patients may also experience bruising or reactions at the injection site. In children, reported adverse reactions include bruising, upper respiratory tract infections, and pain in the mouth or throat. The type and frequency of side effects can vary with age, underlying illness, dose, and other treatments. Some symptoms may be mild, but new or persistent symptoms should be discussed with the treating healthcare professional. Regular follow-up helps distinguish medicine-related effects from symptoms caused by ITP or other medical conditions. Patients should not adjust the dose or stop treatment independently, as platelet counts can change substantially during treatment and after discontinuation.

Important risks associated with romiplostim include thrombotic or thromboembolic events, which may occur if platelet counts rise excessively and can also occur in patients with other risk factors. The medicine may increase bone marrow reticulin, and changes in blood counts or blood-cell morphology may require further assessment. In patients with myelodysplastic syndromes, romiplostim is not an approved treatment for thrombocytopenia in the US label, and concerns include the potential for increased blasts or progression to acute myeloid leukaemia. Severe allergic reactions are also possible. Following discontinuation, platelet counts may fall and the risk of bleeding can increase, particularly in patients taking anticoagulants or antiplatelet medicines. Romiplostim is contraindicated in patients with known hypersensitivity to the active substance or relevant product components. Treatment should be reassessed, interrupted, or discontinued when clinically indicated, with appropriate monitoring and management of platelet counts and bleeding risk.

Before starting romiplostim, clinicians should confirm the cause of thrombocytopenia and obtain a complete blood count, including a peripheral blood smear where appropriate. Patients should be assessed for bleeding, previous thrombosis, cardiovascular risk factors, liver or kidney impairment, and medicines that affect clotting or platelet function. Romiplostim should be used cautiously in patients at increased risk of thromboembolic complications. Monitoring should continue during treatment and after discontinuation because platelet counts may change rapidly. Pregnancy and breastfeeding require an individual assessment of potential benefits and risks. The product contains a biologically active protein, so hypersensitivity to the medicine or its components should be considered. Classic metabolic drug interactions are generally less prominent for biologic medicines such as romiplostim, but concomitant anticoagulants, antiplatelet medicines, and other ITP therapies may affect bleeding risk or the interpretation of platelet responses. Vaccination and infection-related decisions should be individualised according to the patient's overall condition and other treatments.

Confirm that the patient's diagnosis and treatment history meet the applicable indication before prescribing romiplostim. Record baseline platelet counts and other relevant blood parameters, and review the peripheral blood smear when indicated to assess for alternative causes of thrombocytopenia or abnormal blood-cell findings. Explain that the goal is to reduce bleeding risk, not necessarily to achieve a normal platelet count, and that weekly injections and regular blood tests may be needed during dose adjustment. Verify the current body weight, prescribed dose, vial strength, reconstitution instructions, and calculated injection volume carefully, because preparation errors can lead to underdosing or overdosing. Monitor platelet counts according to the product label and assess for signs of thrombosis, new bleeding, or changes suggesting bone marrow abnormalities. Counsel patients not to stop treatment without medical advice, as platelet counts may fall after discontinuation. Document the product and batch number for biological-product traceability, coordinate treatment with other clinicians when anticoagulants or additional ITP therapies are used, and ensure that follow-up continues after treatment ends.